Understanding your child's pathology & risk-group report

A pathology report is a written document produced by a pathologist — a doctor who specialises in examining tissue and cells under a microscope. After your child's biopsy or bone marrow sample has been analysed, the pathologist writes up their findings: what type of cancer cells are present, how the cells look (their grade), whether certain proteins or genetic markers are detectable, and whether cancer cells are present at the surgical margins if a tumour was removed. This report is the cornerstone of your child's diagnosis. The oncology team uses it — together with imaging results and clinical examination — to decide which treatment path to follow. You are entitled to a copy and to ask for a plain-language explanation of every section.

In childhood cancer, particularly in leukaemia and lymphoma, doctors use risk-group classification — low risk, standard risk, or high risk — to decide how intensive treatment needs to be. "High risk" does not mean treatment cannot work. It means that based on specific features of your child's cancer — such as the child's age at diagnosis, the white blood cell count at presentation, the presence of certain chromosome changes (cytogenetics), or whether the cancer has spread beyond its starting point — the disease is less likely to respond to a lighter treatment schedule. High-risk patients receive a more intensive treatment plan specifically designed to improve their outcome. Risk stratification is used precisely because it guides doctors to give every child the right amount of treatment — not too little, not too much.

"Low risk" means that the features of your child's cancer — age, biology, genetic markers, spread — fall into a category where a less intensive treatment protocol has shown good outcomes in large clinical trials. It does not mean the cancer is not serious, and it does not mean your child can skip treatment. It means the treatment plan is calibrated to be effective while causing fewer side effects. Children in the low-risk group are monitored just as carefully during and after treatment. If their cancer does not respond as expected, the risk group can be re-assigned mid-treatment and the plan adjusted. Think of risk group as a starting point, not a final verdict.

Cytogenetics is the study of chromosomes — the structures inside cells that carry genetic information. Cancer cells often have chromosomal abnormalities: chromosomes that are duplicated, deleted, rearranged, or fused in unusual ways. In childhood leukaemia, certain chromosomal changes are very important for risk stratification. For example, having extra chromosomes (hyperdiploidy) in ALL is generally associated with a more favourable outcome, while certain chromosomal rearrangements can mean a higher-risk classification. The cytogenetics section of the pathology report lists these findings using technical shorthand. Your child's oncologist will translate this into plain language and explain exactly what it means for the treatment plan.

Yes. Risk group can be re-assigned based on how the cancer responds to the first phase of treatment. In leukaemia, a test called Minimal Residual Disease (MRD) is performed at specific time points during induction therapy. MRD measures whether tiny numbers of cancer cells are still detectable in the bone marrow. A child who started in the standard-risk group but still has detectable cancer cells after induction may be moved to a higher-risk protocol to receive more intensive treatment. Conversely, a child who started high risk but achieves a very deep early response may be monitored for possible de-escalation in future. This dynamic re-assessment is a strength of modern paediatric oncology — treatment is adjusted based on how the individual child is responding.

Ask for an explanation — every time, without embarrassment. Pathology reports use medical shorthand that is not intended for a general audience. You have the right to ask your child's oncologist to go through every section with you in plain language. Ask what each finding means for treatment, whether a second opinion on the pathology slides is available or advisable, and what the next steps are. At CION Cancer Clinics, our paediatric oncology team holds a 45-minute consultation for every newly diagnosed family, specifically to explain the diagnostic findings and discuss the proposed treatment plan. You deserve to understand what is written about your child's health.